Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner
Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 10a. Adverse Events

Chronic phase—newly diagnosed
Chronic phase—interferon resistant or refractory
Chronic phase—previous stem cell transplant/heavily pretreated
Mixed phase
Accelerated phase
Blastic phase
Imatinib efficacy/other

Phase of CML Chronic phase—newly diagnosed
First Author, Year O'Brien59 Kantarjian55 Kantarjian56
Drug/ dosage imatinib IFN/AraC imatinib IFN/AraC Varied Doses 800mg/d
n n=551 n=553 n=551 n=553 n=114
grade all grades gd3/4 gd3/4 gd3/4
study group historical control
constitutional              
edema or fluid retention           1% 0%
superficial edema 56% 9% 0.9% 0.6%      
periorbital              
leg              
face              
other site              
eyelid              
nausea 44% 61% 0.7% 5.1%      
nausea/vomiting           1% 0%
diarrhea 33% 42% 1.8% 3.2%   1% 0%
myalgia or musculoskeletal pain 1% 1% 1.5/2.7% 1.0% 0.02 3% 2%
muscle cramps 38% 11% 1.3% 0.2%      
fatigue 35% 66% 1.1% 24.4% 0.02 1% 2%
dermatitis or rash 34% 25% 2.0% 2.3% 0.06 6% 6%
headache 31% 43% 0.4% 3.2%      
abdominal pain 2% 25% 2.4% 3.9%      
flatulence              
vomiting 17% 27% 1.5% 3.4%      
hemorrhage 21% 21% 0.7% 1.5%      
tumor hemorrhage              
cerebral hemorrhage              
upper GI tract              
dyspepsia 16% 9% 0.0% 0.8%      
increased lacrimation              
loose stools              
taste disturbance              
neutropenia 61% 67% 14.3% 25.0%   36% 20%
abdominal distension              
abnormal liver-function results 43% 74% 5% 7% 4% 7% 10%
leukopenia              
arthralgia              
paresthesia              
esophageal reflux              
pruritus 7% 12% 0.2% 0.2%      
pain              
blurred vision              
photosensitivity              
nasopharyngitis 22% 8% 0.0% 0.2%      
pyrexia 13% 39% 0.7% 2.8%      
insomnia 12% 19% 0.0% 2.3%      
upper respiratory tract infection 15% 8% 0.2% 0.4%      
granulocytopenia         20%    
thrombocytopenia 57% 79% 8% 17% 8% 25% 12%
anemia 45% 55% 3% 4% 8% 10% 4%
GI symptoms              
weight increase              
cough 15% 22% 0.2% 0.6%      
dyspnea 7% 14% 1.5% 1.5%      
anorexia 5% 32% 0.0% 2.4%      
constipation 9% 14% 0.7% 0.2%      
nasopharingitis              
night sweats 7% 16% 0.2% 0.4%      
epitaxis              
hypokalemia              
petechiae              
pneumonia              
weakness              
asthenia 6% 19% 0.2% 4%      
mucositis              
neuro symptoms              
cardiac           4% 2%
bone or joint aches 28% 40% 2.4% 7%      
infection              
weight gain 13% 2% 0.9% 0.2%      
dizziness 15% 24% 0.9% 3.4%      
prolonged wound healing              
pharyngolaryngeal pain 16% 13% 0.2% 0.2%      
depression 10% 36% 0.4% 13%      
anxiety 7% 11% 0.2% 3%      
rigors 7% 34% 0.0% 0.8%      
influenza like illness 7% 19% 0.0% 0.8%      
alopecia 4% 22% 0.0% 0.6%      
increased sweating 4% 15% 0.0% 0.4%      
weight loss 3% 17% 0.2% 1.3%      
stomatitis 3% 12% 0.0% 0.2%      
dry mouth 2% 10% 0.0% 0.2%      
mucosal inflammation 1% 10% 0.0% 3.2%      
psychiatric              
cardiovascular              
other              
hematologic              

Return to Document
Proceed to Table 10b, Chronic phase—interferon resistant or refractory

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care